Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia.
Wechsler Adult Intelligence Scale
Wechsler Memory Scale
cognitive performance
matrix metalloproteinase-9
schizophrenia
Journal
Neuropsychopharmacology reports
ISSN: 2574-173X
Titre abrégé: Neuropsychopharmacol Rep
Pays: United States
ID NLM: 101719700
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
18
11
2019
revised:
07
01
2020
accepted:
10
01
2020
pubmed:
6
2
2020
medline:
17
8
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Matrix metalloproteinase-9 (MMP-9) has been shown to modulate synaptic plasticity and may contribute to the pathophysiology of schizophrenia. This study investigated the peripheral levels of MMP-9 and its association with cognitive functions in patients with schizophrenia to see the possible involvement of MMP-9 in pathophysiology of schizophrenia, especially in cognitive decline. We measured the plasma levels of MMP-9 in 257 healthy controls and 249 patients with schizophrenia, including antipsychotic drug-free patients. We also explored the possible association between plasma MMP-9 levels and cognitive performance in healthy controls and patients with schizophrenia using the Wechsler Adult Intelligence Scale, Third Edition (WAIS- III), the Wechsler Memory Scale-Revised (WMS-R), and the Rey Auditory Verbal Learning Test (AVLT). We found that the plasma levels of MMP-9 were significantly higher in patients with schizophrenia, including antipsychotic drug-free patients, than in healthy controls. We found a significant negative association between plasma MMP-9 levels and cognitive performance in controls and patients with schizophrenia. Together, these convergent data suggest a possible biological mechanism for schizophrenia, whereby increased MMP-9 levels are associated with cognitive impairment.
Identifiants
pubmed: 32022478
doi: 10.1002/npr2.12098
pmc: PMC7722656
doi:
Substances chimiques
Antipsychotic Agents
0
Biomarkers
0
MMP9 protein, human
EC 3.4.24.35
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-156Informations de copyright
© 2020 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of NeuropsychoPharmacology.
Références
Cell Mol Life Sci. 2019 Aug;76(16):3207-3228
pubmed: 31172215
Clin Chem Lab Med. 2016 Mar;54(3):447-52
pubmed: 26351924
Aging Clin Exp Res. 2016 Dec;28(6):1075-1079
pubmed: 26768000
J Am Heart Assoc. 2018 Jan 6;7(1):
pubmed: 29306898
Psychiatry Res. 2011 May 30;187(3):341-6
pubmed: 20510460
Schizophr Res. 2017 Oct;188:98-109
pubmed: 28100419
PLoS One. 2010 Feb 11;5(2):e9166
pubmed: 20161799
Psychiatry Clin Neurosci. 2017 Feb;71(2):124-134
pubmed: 27891714
Psychiatry Clin Neurosci. 2014 Jul;68(7):534-41
pubmed: 24447376
EMBO Mol Med. 2017 Aug;9(8):1100-1116
pubmed: 28623238
Psychiatry Res. 2011 Nov 30;190(1):163-4
pubmed: 21620482
Schizophr Res. 2009 Apr;109(1-3):90-3
pubmed: 19264454
Am J Psychiatry. 2013 Jun;170(6):683-4
pubmed: 23732972
Int J Neuropsychopharmacol. 2013 Aug;16(7):1483-503
pubmed: 23442539
Schizophr Bull. 2015 Sep;41(5):1003-9
pubmed: 25837304
Schizophr Bull. 2015 Jul;41(4):909-18
pubmed: 25537281
Psychiatry Clin Neurosci. 2017 May;71(5):294-300
pubmed: 27804186
Neurosci Lett. 2013 Nov 27;556:37-41
pubmed: 24141084
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
Neuropsychopharmacol Rep. 2020 Jun;40(2):150-156
pubmed: 32022478